Business Context and Reporting Period
Company: Medifast, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2005
Business Overview: Medifast operates in the weight management and nutritional products sector, utilizing direct sales to consumers, a retail division (Hi-Energy), and the Take Shape for Life division. The company reported strong revenue growth driven by direct marketing campaigns and sales network expansion.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
Three Months Ended June 30, 2005 |
Three Months Ended June 30, 2004 |
|---|---|---|---|---|
| Revenue | $18,881,000 | $14,174,000 | $10,555,000 | $7,357,000 |
| Gross Profit | $14,185,000 | $10,878,000 | $7,932,000 | $5,411,000 |
| Gross Margin | 75.1% | 76.7% | 75.1% | 73.6% |
| Operating Income | $2,066,000 | $1,901,000 | $1,154,000 | $982,000 |
| Net Income | $1,260,000 | $1,321,000 | $753,000 | $674,000 |
| Diluted EPS | $0.10 | $0.11 | $0.06 | $0.06 |
| Cash & Equivalents (End of Period) | $1,229,000 (as of June 30, 2005) | |||
| Working Capital | $8,991,000 (as of June 30, 2005) | |||
| Total Debt (Current + Long-term) | $4,469,000 (as of June 30, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 33% ($4.7M) for the six months ended June 30, 2005, and 43% ($3.2M) for the quarter, driven by direct sales growth and the Take Shape for Life division.
- Expense Increases: Cost of sales rose 42% and Selling, General, and Administrative (SG&A) expenses rose 35% year-over-year for the six-month period. SG&A growth was attributed to operational scaling and the maintenance of eleven start-up retail locations in the Hi-Energy division.
- Profitability: While operating income increased 9% to $2.066M for the six-month period, Net Income decreased slightly by 4.6% to $1.26M due to higher interest expenses and tax provisions.
- Liquidity: Cash and cash equivalents increased from $612,000 at year-end 2004 to $1,229,000 at June 30, 2005. Net cash provided by operating activities was $1.385M, a significant improvement from a $1.91M outflow in the prior year.
- Debt Structure: The line of credit increased to $651,000, and a portion of the line of credit ($369,000) was converted to long-term debt during the period.
Guidance, Outlook, and Risks
- Seasonality: Management notes that traditional seasonality (low sales in Nov/Dec, high in Jan/Feb) is expected to decrease in 2005 due to increased consumer awareness of the health benefits of their products.
- Strategic Initiatives:
- Launched a new "Take Shape America" line of celebrity-endorsed sports performance and weight management products in September 2005.
- Expanded retail presence through an agreement with DrugMax, Inc. to open Hi-Energy Weight Loss Centers.
- Increased strategic testing of television advertising.
- Accounting Changes: The company intends to adopt FAS 123R (Share-Based Payment) effective January 1, 2006, which will require expensing stock-based compensation. The impact is currently being evaluated.
- Legal Contingencies:
- Donavin Litigation: A suit alleging violation of Federal laws regarding Vitamin D3 in meal replacement bars is stayed pending FDA clarification. Management believes the claim lacks merit.
- Bankruptcy Dispute: A dispute exists regarding the ownership of shares transferred by a former consultant to a third party to avoid bankruptcy proceedings. The Trustee in Bankruptcy has deemed the transfer invalid.
- Subsequent Event: On August 2, 2005, the remaining 200,000 shares of Series "C" convertible preferred stock were converted to 400,000 shares of common stock, eliminating all preferred stock from the balance sheet.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 33% revenue growth and the effectiveness of the new direct marketing and TV advertising campaigns.
- Margin Pressure: Monitor the trend in Gross Margins, which dipped slightly from 76.7% to 75.1% year-over-year, alongside the 42% increase in Cost of Sales.
- SG&A Efficiency: Assess whether the 35% increase in SG&A expenses will stabilize as the eleven new retail locations mature.
- Debt Obligations: Review the terms of the line of credit and long-term debt, noting the recent conversion of credit line funds to long-term debt.
- Legal Risks: Track the status of the Vitamin D3 litigation and the bankruptcy estate dispute regarding share ownership.
- Accounting Impact: Evaluate the potential impact of the upcoming FAS 123R adoption on future net income and EPS.